CDK1 and cancer: The other distinct class includes CDK inhibitors that are more selective for CDK1 and CDK2 as well as the transcriptional CDKs (CDK5, CDK7, and CDK9), and these drugs are being more widely studied in cancers including triple-negative breast cancer [19].